Three cases of COVID-19 patients presenting with erythema.
COVID-19
cutaneous manifestations
eruption
erythema
rash
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
08
06
2020
revised:
22
06
2020
accepted:
04
07
2020
pubmed:
4
9
2020
medline:
15
12
2020
entrez:
4
9
2020
Statut:
ppublish
Résumé
Individuals infected with the novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) who develop coronavirus disease 2019 (COVID-19) experience many symptoms; however, cutaneous manifestations are relatively rare. The authors encountered three patients with COVID-19 who presented with erythema and suspected viral rash. In all cases, erythema appeared after the onset of the initial symptoms of COVID-19. Erythema was considered to be caused by COVID-19 and not a drug-induced eruption because, in all cases, erythema was relieved merely by external medicine and oral antihistamines, without discontinuing the original medication. The authors' hospital accepted 69 COVID-19 patients between 22 February 2020 and 31 May 2020 and, of these, three (4.3%) exhibited eruptions, and all cases presented erythema. Except for seven patients who exhibited positive nasopharyngeal swab tests for SARS-CoV-2 RNA but no symptoms, three (4.8%) of the remaining 62 patients exhibited erythema. Although various types of eruptions have been reported in patients with COVID-19, erythema was the only type in our patients. Erythema in the three patients exhibited many similarities to that previously reported in COVID-19 patients, particularly in the manner it appeared and disappeared. For these reasons, these three cases were considered typical examples of erythema in patients with COVID-19. Considering previous studies and the three cases reported here, there is a high probability that SARS-CoV-2 can cause erythema.
Identifiants
pubmed: 32881072
doi: 10.1111/1346-8138.15532
pmc: PMC7461553
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1175-1178Informations de copyright
© 2020 Japanese Dermatological Association.
Références
Br J Dermatol. 2020 Jul;183(1):71-77
pubmed: 32348545
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e453-e454
pubmed: 32358895
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Exp Dermatol. 2020 Oct;45(7):892-895
pubmed: 32385858
Br J Dermatol. 2020 Aug;183(2):e31
pubmed: 32353170
An Pediatr (Engl Ed). 2020 Jun;92(6):374-375
pubmed: 32341944
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e246-e247
pubmed: 32294259
JAAD Case Rep. 2020 Apr 28;6(6):537-539
pubmed: 32346588
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Int J Dermatol. 2020 Jul;59(7):874-875
pubmed: 32358979
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e299-e300
pubmed: 32314436
J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213
pubmed: 32215952
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e304-e306
pubmed: 32330336
J Dermatol Sci. 2020 May;98(2):75-81
pubmed: 32381430